Cyrus Biotechnology Inc. has selected CYR-212, an engineered next-generation reduced-immunogenicity and half-life extended immunoglobulin G (IgG) protease, as a clinical development candidate for ...

Kidney inflammation caused by SLE is referred to as lupus nephritis ... becoming the first oral alternative to GSK's injectable anti-BLyS/BAFF antibody Benlysta (belimumab) for the treatment ...

For the patient who presents with a new diagnosis of SLE, or for the one who has a flare in previously established disease, the immediate need is to achieve control of the inflammatory process.

Autoimmune diseases are a pathophysiological state wherein immune responses are directed against, and damage, the body's own tissues (autoimmunity). Common examples of autoimmune disease include ...

The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target ...

Agents such as azathioprine, methotrexate and cyclosporine A have been used for several decades in the management of SLE, but the evidence for their efficacy in nonrenal lupus has remained limited.

The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. With the growing use ...